This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/528998-italy-vaccine-covid19-trial/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial | Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial |
| (about 2 months later) | |
| An Italian firm has published promising results from its phase-two clinical trials, in which its Covid-19 vaccine induced an antibody response in 93% of volunteers three weeks after the first dose, reaching 99% after the second. | An Italian firm has published promising results from its phase-two clinical trials, in which its Covid-19 vaccine induced an antibody response in 93% of volunteers three weeks after the first dose, reaching 99% after the second. |
| In a press statement on Monday, Italian biotech company ReiThera said its candidate vaccine was well tolerated and “induces clear immune responses in trial subjects.” | In a press statement on Monday, Italian biotech company ReiThera said its candidate vaccine was well tolerated and “induces clear immune responses in trial subjects.” |
| The vaccine, called GRAd-COV2, generated an antibody response against the virus’s spike protein in over 93% of volunteers after the first dose, reaching 99% after the second. | The vaccine, called GRAd-COV2, generated an antibody response against the virus’s spike protein in over 93% of volunteers after the first dose, reaching 99% after the second. |
| The study involved 917 volunteers over the age of 18 at 24 centers across Italy. A quarter of volunteers were either over the age of 65 or had conditions associated with an increased risk of severe Covid-19. | The study involved 917 volunteers over the age of 18 at 24 centers across Italy. A quarter of volunteers were either over the age of 65 or had conditions associated with an increased risk of severe Covid-19. |
| “We are very excited about the preliminary phase two data,” said Roberto Camerini, ReiThera’s medical director, adding: “Our vaccine candidate confirmed its excellent safety and good immunogenicity profile in a large cohort. ReiThera reaffirms its commitment to the fight against Covid-19 in the face of pressing global demand for additional vaccines.” | “We are very excited about the preliminary phase two data,” said Roberto Camerini, ReiThera’s medical director, adding: “Our vaccine candidate confirmed its excellent safety and good immunogenicity profile in a large cohort. ReiThera reaffirms its commitment to the fight against Covid-19 in the face of pressing global demand for additional vaccines.” |
| While the company’s statement says that independent advisory boards recommend continuing the trial and advancing to phase three, ReiThera will need at least 60 million euros ($71 million) to fund the final-phase trial. In May, a state audit court rejected a plan that would pump public money into the firm. | While the company’s statement says that independent advisory boards recommend continuing the trial and advancing to phase three, ReiThera will need at least 60 million euros ($71 million) to fund the final-phase trial. In May, a state audit court rejected a plan that would pump public money into the firm. |
| ReiThera has already held early talks with the EU concerning a possible deal that would see Brussels diversify its supply of vaccines, which is currently highly reliant on shots provided by Pfizer and Moderna. | ReiThera has already held early talks with the EU concerning a possible deal that would see Brussels diversify its supply of vaccines, which is currently highly reliant on shots provided by Pfizer and Moderna. |
| Moderna’s CEO Stephane Bancel has previously warned that the world may have an oversupply of Covid-19 vaccines in 2022, as firms such as themselves hugely increase vaccine manufacturing capacity, and this could be challenging for developers. | Moderna’s CEO Stephane Bancel has previously warned that the world may have an oversupply of Covid-19 vaccines in 2022, as firms such as themselves hugely increase vaccine manufacturing capacity, and this could be challenging for developers. |
| If you like this story, share it with a friend! | If you like this story, share it with a friend! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |